Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol

Journal of Affective Disorders

Volumn 144, Issue 3, 2013, Pages 191-198

  Goikolea, J M ^a   Colom, F ^a   Torres, I ^a   Capapey, J ^a   Valenti M ^a   Undurraga, J ^a   Grande, I ^a   Sanchez Moreno, J ^a   Vieta, E ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antipsychotics; Depressive switch; Mania; Meta analysis

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

DEPRESSION; DRUG EFFICACY; HUMAN; MANIA; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

ACUTE DISEASE; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DEPRESSION; DEPRESSIVE DISORDER; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG INDUSTRY; HALOPERIDOL; HUMANS; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH SUPPORT AS TOPIC; RISPERIDONE; THIAZOLES;

EID: 84870549409     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2012.07.038     Document Type: Review

References (36)

1. J. Angst Switch from depression to mania, or from mania to depression Journal of Psychopharmacology 1 1987 13 19
2. R,H. Belmaker Bipolar disorder New England Journal of Medicine 351 2004 476 486
3. Cipriani, A., Rendell, J.M., Geddes, J.R., 2006. Haloperidol Alone or in Combination for Acute Mania. Cochrane Database of Systematic Reviews (3), Art. no.: CD004362. doi:0.1002/14651858.CD004362.pub2.
4. A. Cipriani, C. Barbui, G. Salanti, J. Rendell, R. Brown, S. Stockton, M. Purgato, L.M. Spineli, G.M. Goodwin, and J.R. Geddes Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis Lancet 378 2011 1306 1315
5. Clarke, M., Oxman, A.D., 2000. Cochrane Collaboration Handbook, Version 4.0 (updated July 2000). The Cochrane Library, Oxford.
6. F. Colom, and E. Vieta The need for publishing the silent evidence from negative trials Acta Psychiatrica Scandinavica 123 2011 91 94
7. N. Cruz, J. Sanchez-Moreno, F. Torres, J.M. Goikolea, M. Valentí, and E. Vieta Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis International Journal of Neuropsychopharmacology 13 2010 5 14
8. Deeks, J.J., Higgins, J.P.T., Altman, D.G. (Eds.), 2011. Analysing data and undertaking meta-analyses. In: Higgins, J.P.T., Green, S. (Eds.). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration (Chapter 9). Available from: 〈http://www.cochrane-handbook.org〉.
9. Egger, M., Smith, G.D., O'Rourke, K., 2001. Rationale, Potentials, and Promise of Systematic Reviews. In: Systematic Reviews in Health Care: Meta-Analysis in Context. BMJ Publishing Group, London, pp. 3-22.
10. G.M. Goodwin, and Consensus Group of the British Association for Psychopharmacology Evidence-based guidelines for treating bipolar disorder: revised second edition - recommendations from the British Association for Psychopharmacology Journal of Psychopharmacology 23 2009 346 388
11. H. Grunze, E. Vieta, G.M. Goodwin, C. Bowden, R.W. Licht, Moller, and S.H.J. Kasper The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania World Journal of Biological Psychiatry 10 2009 85 116
12. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Statistics in Medicine 21 2002 1539 1558
13. Higgins, J.P.T., Altman, D.G., Sterne, J.A.C. (Eds.), 2011. Assessing risk of bias in included studies. In: Higgins, J.P.T., Green, S. (Eds.). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration (Chapter 8). Available from: 〈http://www.cochrane-handbook.org〉.
14. R. McIntyre, M. Brecher, B. Paulsson, K. Huizar, and J. Mullen Quetiapine or haloperidol as monotherapy for bipolar mania: a 12 weeks double blind, randomised, parallel group, placebo controlled trial European Neuropsychopharmacology 15 2005 573 585
15. D. Moher, D.J. Cook, S. Eastwood, I. Olkin, D. Rennie, and D.F. Stroup Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses Lancet 354 1999 1896 1900
16. A.M. Nivoli, A. Murru, J.M. Goikolea, J.M. Crespo, J.M. Montes, A. González-Pinto, P. García-Portilla, J. Bobes, J. Sáiz-Ruiz, and E. Vieta New treatment guidelines for acute bipolar mania: a critical review Journal of Affective Disorders 140 2012 125 141
17. D. Popovic, M. Reinares, J.M. Goikolea, C.M. Bonnin, A. Gonzalez-Pinto, and E. Vieta Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder European Neuropsychopharmacology 22 2012 339 346
18. Review Manager (RevMan) [Computer program], 2003. Version 4.2 for Windows. Oxford: Cochrane Collaboration.
19. G. Sachs, F. Grossman, S.N. Ghaemi, A. Okamoto, and C.L. Bowden Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety American Journal of Psychiatry 159 2002 1146 1154
20. J. Segal, M. Berk, and S. Brook Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial Clinical Neuropharmacology 21 1998 176 180
21. A.B. Smulevich, S. Khanna, M. Eerdekens, K. Karcher, M. Kramer, and F. Grossman Acute and continuation risperidone monotherapy in bipolar mania: a 3 week placebo controlled trial followed by a 9 week double blind trial of risperidone and haloperidol European Neuropsychopharmacology 15 2005 75 84
22. M. Tohen, C.A. Zarate, J. Hennen, H.M. Kaur Khalsa, S.M. Strakowski, P. Gebre-Medhin, P. Salvatore, and R.J. Baldessarini The McLean-Harvard first-episode mania study: prediction of recovery and first recurrence American Journal of Psychiatry 160 2003 2099 2107
23. M. Tohen, J. Goldberg, A. Gonzalez-Pinto Arrillaga, J.M. Azorin, E. Vieta, M.C. Hardy-Bayle, W.B. Lawson, R.A. Emsley, F. Zhang, R.W. Baker, R.C. Risser, M.A. Namjoshi, A.R. Evans, and A. Breier A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania Archives of General Psychiatry 60 2003 1218 1226
24. M. Tohen, and E. Vieta Antipsychotic agents in the treatment of bipolar mania Bipolar Disorders 11 Suppl. 2 2009 S45 S54
25. M. Valentí, I. Pacchiarotti, C.M. Bonnín, A.R. Rosa, D. Popovic, A.M. Nivoli, J.M. Goikolea, A. Murru, J. Undurraga, F. Colom, and E. Vieta Risk factors for antidepressant-related switch to mania Journal of Clinical Psychiatry 73 2012 e271 e276
26. E. Vieta The treatment of mixed states and the risk of switching to depression European Psychiatry 20 2005 96 100
27. E. Vieta, M. Bourin, R. Sanchez, R. Marcus, E. Stock, R. McQuade, W. Carson, N. Abou-Gharbia, R. Swanink, T. Iwamoto, and Aripiprazole Study Group Effectiveness of Aripiprazole vs haloperidol in acute bipolar mania: double blind, randomised, comparative 12 week trial British Journal of Psychiatry 187 2005 235 242
28. E. Vieta, J. Angst, C. Reed, J. Bertsch, J.M. Haro, and EMBLEM advisory board Predictors of switching from mania to depression in a large observational study across Europe (EMBLEM) Journal of Affective Disorders 118 2009 118 123
29. E. Vieta, T. Ramey, D. Keller, P.A. English, A.D. Loebel, and J. Miceli Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study Journal of Psychopharmacology 24 2010 547 558
30. E. Vieta, I.F. Nuamah, P. Lim, E.C. Yuen, J.M. Palumbo, D.W. Hough, and J. Berwaerts A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder Bipolar Disorders 12 2010 230 243
31. E. Vieta, E. Pappadopulos, F.S. Mandel, and I. Lombardo Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study International Journal of Neuropsychopharmacology 14 2011 1017 1027
32. A. Yildiz, E. Vieta, S. Leucht, and R.J. Baldessarini Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials Neuropsychopharmacology 36 2011 375 389
33. Vieta, E., Cruz, N., Head to head comparisons as an alternative to placebo-controlled trials. European Neuropsychopharmacology, http://dx.doi.org/10.1016/j.euroneuro.2011.11.011, in press.
34. L.N. Yatham, S.H. Kennedy, A. Schaffer, S.V. Parikh, S. Beaulieu, C. O'Donovan, G. MacQueen, R.S. McIntyre, V. Sharma, A. Ravindran, L.T. Young, A.H. Young, M. Alda, R. Milev, E. Vieta, J.R. Calabrese, M. Berk, K. Ha, and F Kapczinski Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009 Bipolar Disorder 11 2009 225
35. A.H. Young, D.A. Oren, A. Lowy, R.D. McQuade, R.N. Marcus, W.H. Carson, N.H. Spiller, A.F. Torbeyns, and R. Sanchez Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study British Journal of Psychiatry 194 2009 40 48
36. C.A. Zarate Jr., and M. Tohen Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients American Journal of Psychiatry 161 2004 169 171